TORONTO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that candidates from its Family 3 compounds…


Previous articleMYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering
Next articleScientists Isolate Two New Compounds from Toad Venom